BAG3 and cancer: Given the prevalence of drug resistance, the observed ALP/UPS compensation, and the predominance of recurrence, the intracellular and extracellular regulator Bag3 offers a stress-sensitive and, therefore, cancer-cell specific target to effectively re-sensitize malignant cells to PQC oversight, even in the presence of a heterogeneous molecular profile.